Compare SPIR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPIR | AARD |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.1M | 281.1M |
| IPO Year | 2020 | N/A |
| Metric | SPIR | AARD |
|---|---|---|
| Price | $8.54 | $12.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $13.10 | ★ $31.11 |
| AVG Volume (30 Days) | ★ 549.7K | 103.5K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $110,451,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $3.65 | ★ N/A |
| Revenue Growth | ★ 13.15 | N/A |
| 52 Week Low | $6.60 | $4.88 |
| 52 Week High | $14.53 | $17.94 |
| Indicator | SPIR | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 47.89 |
| Support Level | $7.05 | $12.70 |
| Resistance Level | $8.56 | $13.24 |
| Average True Range (ATR) | 0.81 | 0.78 |
| MACD | -0.27 | 0.02 |
| Stochastic Oscillator | 1.32 | 68.10 |
Spire Global Inc is a provider of space-based data, analytics, and Space Services, offering datasets and powerful insights about Earth from the ultimate vantage point of space so that organizations can make decisions with confidence, accuracy, and speed. It generates revenue from four solutions: Maritime, Aviation, Weather, and Space Services. It offers the following three data solutions to customers; Maritime-precise space-based data used for accurate ship monitoring, ship safety, and route optimization, Aviation-precise space-based data used for accurate aircraft monitoring, aircraft safety, and route optimization, and Weather-precise space-based data used for accurate weather forecasting.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.